Skip to main content
Equibles
SCLX logo

SCLX · Scilex Holding Co · Metrics

Track SCLX — free

Use SCLX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SCLX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.01 -0.04 (-0.79%) At close · Sep 11
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company's ability to continue as a going concern for one year after the date the unaudited condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 14, 2026
Customer concentration — top 4 customers 96% of revenue

4 customers — 96% of revenue (the three months ended June 30, 2026)

“The Company had four customers during the three and six months ended June 30, 2026, each of which individually generated 10% or more of the Company’s total revenue. These customers accounted for 96% and 95% of the Company’s revenue for the three and six months ended June 30, 2026, respectively, individually ranging from 22% to 27% and 19% to 27%.”

4 customers — 95% of revenue (the six months ended June 30, 2026)

“The Company had four customers during the three and six months ended June 30, 2026, each of which individually generated 10% or more of the Company’s total revenue. These customers accounted for 96% and 95% of the Company’s revenue for the three and six months ended June 30, 2026, respectively, individually ranging from 22% to 27% and 19% to 27%.”

4 customers — 80% of receivables (As of June 30, 2026)

“As of each of June 30, 2026 and 2025, these customers represented 80% and 99% of the Company’s outstanding accounts receivable, individually ranging between 16% and 37%, and 19% and 30% for respective periods.”
View the 10-Q filed Aug 14, 2026
Market Cap
$42.55M
Shares
8.49M

SCLX metrics

49 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$5.01
Market cap
$42.55M

Price action

20 metrics
Price change (1W)
-7.5%
Price change (30D)
-25.9%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
89.6%
Annualized volatility (3M)
—
Beta
—
RSI (14D)
28.7
Price vs SMA 50
-26.6%
Price vs SMA 200
—
Avg volume (3M)
108,072
Relative volume
0.2
Average dollar volume
$815,178

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - General
Shares outstanding
8.49M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.3×
reciprocal yield 74.3%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,091.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
415.8%
Operating margin
-1,136.4%
Trailing 12 months
Net margin
-1,469.8%
Gross profit (TTM)
$110.10M
Operating profit (TTM)
−$359.19M
Net income (TTM)
−$464.56M
Trailing 12 months
Diluted EPS (TTM)
$-34.45
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-18.40

Growth

11 metrics
Revenue growth YoY
-22.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$31.61M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-40.6%
Year over year · fewer shares
Revenue CAGR (3Y)
-7.3%
Revenue CAGR (5Y)
+5.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-183.2%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
−$350.88M
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
-22.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$566,000
Total assets
$253.56M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$17.09M
Capital expenditures (TTM)
$726,000
R&D (TTM)
$18.61M
SG&A (TTM)
$277.98M
Stock compensation (TTM)
$16.12M
R&D / revenue
58.9%
Stock compensation / revenue
51.0%

Ownership (13F)

3 metrics
13F filers
76
13F filer change QoQ
-1
Institutional ownership
9.8%

Short interest

3 metrics
Short interest
1.9%
Latest settlement · 3.1 days to cover
Days to cover
3.1d
Short-squeeze score
41 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1820190 CUSIP 80880W205 13F (30d) 1 filings 1 filers Visit website Investor relations